6CEZ

Crystal Structure of Rabbit Anti-HIV-1 gp120 V2 Fab 16C2 in complex with V2 peptide ConB

  • Classification: IMMUNE SYSTEM
  • Expression System: Homo sapiens

  • Deposited: 2018-02-13 Released: 2018-09-12 
  • Deposition Author(s): Kong, X., Pan, R.
  • Funding Organization(s): National Institutes of Health/National Institute Of Allergy and Infectious Diseases 

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.399 Å
  • R-Value Free: 0.296 
  • R-Value Work: 0.237 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to alpha 4 beta 7.

Lertjuthaporn, S.Cicala, C.Van Ryk, D.Liu, M.Yolitz, J.Wei, D.Nawaz, F.Doyle, A.Horowitch, B.Park, C.Lu, S.Lou, Y.Wang, S.Pan, R.Jiang, X.Villinger, F.Byrareddy, S.N.Santangelo, P.J.Morris, L.Wibmer, C.K.Biris, K.Mason, R.D.Gorman, J.Hiatt, J.Martinelli, E.Roederer, M.Fujikawa, D.Gorini, G.Franchini, G.Arakelyan, A.Ansari, A.A.Pattanapanyasat, K.Kong, X.P.Fauci, A.S.Arthos, J.

(2018) PLoS Pathog. 14: e1007278-e1007278

  • DOI: 10.1371/journal.ppat.1007278

  • PubMed Abstract: 
  • The GI tract is preferentially targeted during acute/early HIV-1 infection. Consequent damage to the gut plays a central role in HIV pathogenesis. The basis for preferential targeting of gut tissues is not well defined. Recombinant proteins and synth ...

    The GI tract is preferentially targeted during acute/early HIV-1 infection. Consequent damage to the gut plays a central role in HIV pathogenesis. The basis for preferential targeting of gut tissues is not well defined. Recombinant proteins and synthetic peptides derived from HIV and SIV gp120 bind directly to integrin α4β7, a gut-homing receptor. Using both cell-surface expressed α4β7 and a soluble α4β7 heterodimer we demonstrate that its specific affinity for gp120 is similar to its affinity for MAdCAM (its natural ligand). The gp120 V2 domain preferentially engages extended forms of α4β7 in a cation -sensitive manner and is inhibited by soluble MAdCAM. Thus, V2 mimics MAdCAM in the way that it binds to α4β7, providing HIV a potential mechanism to discriminate between functionally distinct subsets of lymphocytes, including those with gut-homing potential. Furthermore, α4β7 antagonists developed for the treatment of inflammatory bowel diseases, block V2 binding to α4β7. A 15-amino acid V2 -derived peptide is sufficient to mediate binding to α4β7. It includes the canonical LDV/I α4β7 binding site, a cryptic epitope that lies 7-9 amino acids amino terminal to the LDV/I, and residues K169 and I181. These two residues were identified in a sieve analysis of the RV144 vaccine trial as sites of vaccine -mediated immune pressure. HIV and SIV V2 mAbs elicited by both vaccination and infection that recognize this peptide block V2-α4β7 interactions. These mAbs recognize conformations absent from the β- barrel presented in a stabilized HIV SOSIP gp120/41 trimer. The mimicry of MAdCAM-α4β7 interactions by V2 may influence early events in HIV infection, particularly the rapid seeding of gut tissues, and supports the view that HIV replication in gut tissue is a central feature of HIV pathogenesis.


    Organizational Affiliation

    Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Light chain of Fab fragment of rabbit anti-HIV1 gp120 V2 mAb 16C2
L
213N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Heavy chain of Fab fragment of rabbit anti-HIV1 gp120 V2 mAb 16C2
H
225N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
HIV-1 gp120 V2 Peptide Con B
P
15N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.399 Å
  • R-Value Free: 0.296 
  • R-Value Work: 0.237 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 64.145α = 90.00
b = 41.470β = 91.68
c = 79.893γ = 90.00
Software Package:
Software NamePurpose
XDSdata reduction
PHENIXphasing
PHENIXrefinement
XDSdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data

  • Deposited Date: 2018-02-13 
  • Released Date: 2018-09-12 
  • Deposition Author(s): Kong, X., Pan, R.

Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute Of Allergy and Infectious DiseasesUnited StatesAI082274
National Institutes of Health/National Institute Of Allergy and Infectious DiseasesUnited StatesAI082676
National Institutes of Health/National Institute Of Allergy and Infectious DiseasesUnited StatesAI065250
National Institutes of Health/National Institute Of Allergy and Infectious DiseasesUnited StatesAI100151

Revision History 

  • Version 1.0: 2018-09-12
    Type: Initial release
  • Version 1.1: 2019-02-20
    Type: Author supporting evidence, Data collection